Xanomeline
Xanomeline is a muscarinic acetylcholine receptor agonist that has been studied for its potential therapeutic uses, particularly in the treatment of Alzheimer's disease and schizophrenia. It was first synthesized in the late 20th century and has been the subject of numerous clinical trials.
History
Xanomeline was first synthesized in the 1990s by scientists at Lilly Research Laboratories. The compound was developed as a potential treatment for Alzheimer's disease and schizophrenia, due to its ability to stimulate muscarinic acetylcholine receptors in the brain.
Pharmacology
Xanomeline is a muscarinic acetylcholine receptor agonist. It has a high affinity for the M1 and M4 subtypes of this receptor, which are primarily found in the brain. By stimulating these receptors, xanomeline can increase the activity of the cholinergic system, which is often impaired in individuals with Alzheimer's disease and schizophrenia.
Clinical Trials
Several clinical trials have been conducted to evaluate the efficacy of xanomeline in treating Alzheimer's disease and schizophrenia. In a phase II trial conducted by Lilly Research Laboratories, xanomeline was found to improve cognitive function and reduce psychotic symptoms in patients with Alzheimer's disease. However, the drug also caused significant side effects, including nausea and increased salivation, which led to the discontinuation of the trial.
Current Status
As of 2021, xanomeline is not approved for use in any country. However, research into its potential therapeutic uses continues. A prodrug of xanomeline, known as KarXT, is currently being developed by Karuna Therapeutics for the treatment of schizophrenia and other psychiatric disorders.
See Also
| Alzheimer's disease topics | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
This Alzheimer's disease related article is a stub.
|
| Schizophrenia | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
* Category
|
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
